LON:DOCS Dr. Martens (DOCS) Share Price, News & Analysis GBX 55.50 -0.75 (-1.33%) As of 11:47 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock About Dr. Martens Stock (LON:DOCS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dr. Martens alerts:Sign Up Key Stats Today's Range 55.25▼ 5950-Day Range 47.98▼ 61.0552-Week Range 43.02▼ 93.25Volume837,095 shsAverage Volume2.28 million shsMarket Capitalization£538.77 millionP/E Ratio7.87Dividend Yield5.41%Price TargetGBX 6,000Consensus RatingHold Company OverviewDr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index. Dr. Martens operates across three geographic regions: EMEA, Americas and APAC. Our product segments include Originals, Fusion, Kids and Casual and a complementary range of Accessories.Read More… Dr. Martens Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreDOCS MarketRank™: Dr. Martens scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingDr. Martens has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDr. Martens has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Martens' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Martens is 7.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Martens is 7.87, which means that it is trading at a less expensive P/E ratio than the Consumer Cyclical sector average P/E ratio of about 89.29.Price to Earnings Growth RatioDr. Martens has a PEG Ratio of 6.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Martens has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DOCS. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Martens pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Martens does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Martens is 42.53%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Dr. Martens' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for DOCS. News and Social Media1.6 / 5News Sentiment-0.19 News SentimentDr. Martens has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Consumer Cyclical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dr. Martens this week, compared to 2 articles on an average week.Search Interest22 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Dr. Martens insiders have bought more of their company's stock than they have sold. Specifically, they have bought £17,927.71 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 4.36% of the stock of Dr. Martens is held by insiders.Percentage Held by Institutions69.53% of the stock of Dr. Martens is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dr. Martens' insider trading history. Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Martens and its competitors with MarketBeat's FREE daily newsletter. Email Address DOCS Stock News HeadlinesRoyal Bank of Canada Issues Pessimistic Forecast for Dr. Martens (LON:DOCS) Stock PriceMay 21 at 1:31 AM | americanbankingnews.comThis FTSE 250 icon’s been very quiet. What’s going on?May 20 at 6:07 AM | msn.comWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.May 22, 2025 | Priority Gold (Ad)Doc Martens rare deal drops price to just $85: ‘I don’t want to take them off’May 9, 2025 | msn.comDoc Martens sale is so good you’ll regret missing out - Prices start at $64.99May 8, 2025 | msn.comBest selling Doc Martens are under $100 right nowMay 8, 2025 | msn.comIs The Market Rewarding Dr. Martens plc (LON:DOCS) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?May 7, 2025 | finance.yahoo.comBestselling Dr. Martens sandals that are 'so comfy from day one' are slashed by £42April 26, 2025 | mirror.co.ukSee More Headlines DOCS Stock Analysis - Frequently Asked Questions How have DOCS shares performed this year? Dr. Martens' stock was trading at GBX 72.20 at the beginning of the year. Since then, DOCS stock has decreased by 23.1% and is now trading at GBX 55.50. View the best growth stocks for 2025 here. How were Dr. Martens' earnings last quarter? Dr. Martens plc (LON:DOCS) announced its quarterly earnings data on Thursday, November, 28th. The company reported ($1.30) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a trailing twelve-month return on equity of 18.91%. Read the conference call transcript. How do I buy shares of Dr. Martens? Shares of DOCS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Dr. Martens own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Martens investors own include boohoo group (BOO), Aston Martin Lagonda Global (AML), ASOS (ASC), Vodafone Group Public (VOD), JD Sports Fashion (JD), Legal & General Group (LGEN) and Lloyds Banking Group (LLOY). Company Calendar Last Earnings11/28/2024Record date for 4/8 Dividend3/06/2025Ex-Dividend for 4/8 Dividend3/06/2025Dividend Payable4/08/2025Today5/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorConsumer Cyclical Industry Footwear & Accessories Sub-IndustryComputer Software Current SymbolLON:DOCS CIKN/A Webwww.drmartensplc.com Phone44 12 1415 7047FaxN/AEmployees890Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 6,000 High Stock Price TargetGBX 6,000 Low Stock Price TargetGBX 6,000 Potential Upside/Downside+10,710.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 7.05 Trailing P/E Ratio7.87 Forward P/E Ratio21.50 P/E Growth6.4Net Income£68.97 million Net Margins7.89% Pretax MarginN/A Return on Equity18.91% Return on Assets8.12% Debt Debt-to-Equity Ratio127.27 Current Ratio2.85 Quick Ratio1.13 Sales & Book Value Annual Sales£874.20 million Price / Sales0.62 Cash FlowGBX 3.89 per share Price / Cash Flow14.29 Book ValueGBX 37.80 per share Price / Book1.47Miscellaneous Outstanding Shares970,763,405Free FloatN/AMarket Cap£538.77 million OptionableNot Optionable Beta0.11 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (LON:DOCS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Martens plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Martens With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.